SBIR/STTR Research Award

Discovery of Novel Drugs for Autism

Award identifier 3e65e306d9825ff927a614f1816c3a7e1dba30717914da2de3611433b500afc2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$771,464

Program and phase

STTR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ASDDR, LLC
Proposal award date
2017-06-29
Contract end date
2020-05-31
UEI
Not reported
Solicitation number
PA14-196
Topic code
101

Research abstract

Summary The goal of this study is to discover novelmechanism based pharmacological intervention for autisma devastating neurodevelopmental disorder with no treatment currentlyGenetic sequencing has revealed extensive overlap in risk genes for autism and for cancermany of which are chromatin remodeling factors important for transcriptional regulationsuggesting the possibility of repurposing the anti cancer drugs targeting epigenetic enzymes for autism treatmentASDDR LLC and Yan Lab at SUNY Buffalo propose to jointly investigate the hypothesis that histone deacetylaseHDACinhibitors are able to restore the expression of key autism risk factors and induce long lasting rescue of autism like behavioral and synaptic deficitsCombined behavioralbiochemical and electrophysiological approaches will be used to address two specific aimsAimTo discover HDAC inhibitors that can alleviate autism like behavioral deficits in autism mouse modelsYan lab screened a number of drugs and found that a brief treatment with the highly potent and class I specific HDAC inhibitorromidepsinIstodaxan FDA approved anti cancer agentat the very low doseled to dramatic and prolonged rescue of the social deficits in the Shankdeficient mouse model of autismTo determine whether this pharmacological agent can serve as a tool compound for autism drug developmentits therapeutic efficacy and safety will be examined in two different models of autismShankdeficient mice and BTBR miceAimTo identify the molecular targets of HDAC inhibitors as benchmarks for the treatment of autismFor the discovery of effective drugs to treat autismthe molecular pathways on which HDAC inhibitors act to alleviate the autism like behavioral deficits in Shankdeficient mice need to be understoodWe will reveal the potential benchmarksuch as actin regulators and NMDARsas molecular targets of romidepsinThis phase I preclinical study will provide great promise for the discovery of new and effective pharmacological agents to treat the social interaction deficitsa core symptom of autism

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.